Investigational drug · Phase 2
MenACWY
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Shigellosis, Salmonella Infections.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
94
Any phase or sponsor naming "MenACWY"
First trial start
2024
Jan 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MenACWY", any sponsor or status.
Conditions studied
As listed on its trial records.
- Shigellosis
- Salmonella Infections
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "MenACWY" as an intervention, largest first.
PfizerPfizer (PFE)
NCT05873751 · 1,307,378 participants · Start Apr 24, 2023 · Primary completion Mar 31, 2024
Drug: Trumenba Vaccine; MenACWY Vaccine · For: Gonorrhea; Chlamydia; Meningococcal Vaccines
Sites: New York, New York
Novartis VaccinesNovartis (NVS)
NCT01452464 · 55,397 participants · Start Sep 2011 · Primary completion Feb 2015
Drug: MenACWY-CRM · For: Meningococcal Disease
Sites: Riverside, California; San Diego, California; Valley Annex, 16994 E. Valley Blvd., Fontana, California
- Investigating a Vaccine Against COVID-19Pivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT04400838 · 10,811 participants · Start May 28, 2020 · Primary completion Feb 5, 2025
Drug: ChAdOx1 nCoV-19 (Abs 260); MenACWY vaccine and 7 more · For: Coronavirus
Sites: Southampton, United Kingdom; Cottingham, United Kingdom; London, United Kingdom · 20 sites in all
- A Study of a Candidate COVID-19 Vaccine (COV003)Pivotal-lookingStatus unknown
University of OxfordAcademic, hospital or other
NCT04536051 · 10,300 participants (planned) · Start Jun 2, 2020 · Primary completion Sep 2021
Drug: ChAdOx1 nCoV-19 single dose + paracetamol; MenACWY single dose + paracetamol and 2 more · For: Coronavirus
Sites: Salvador, Brazil; Natal, Brazil; Porto Alegre, Brazil · 6 sites in all
- Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00806195 · 7,744 participants · Start Dec 2008 · Primary completion Mar 2011
Drug: MenACWY-CRM197; DTaP (Diptheria, Tetanus, Pertussis) Vaccine and 6 more · For: Meningitis; Meningococcal Infection
Sites: Birmingham, Alabama; Dothan, Alabama; Tuscon, Arizona · 153 sites in all
- A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In InfantsPivotal-lookingCompleted
Novartis VaccinesNovartis (NVS)
NCT00474526 · 4,545 participants · Start Mar 2007 · Primary completion Sep 2008
Drug: Meningococcal ACWY Conjugate Vaccine; DTaP-IPV-HBV and 6 more · For: Meningitis, Meningococcal
Sites: Bessemer, Alabama; Birmingham, Alabama; Downey, California · 63 sites in all
GlaxoSmithKlineGSK (GSK)
NCT01766206 · 3,948 participants · Start Mar 15, 2013 · Primary completion Jan 22, 2018
Drug: MenACWY-CRM (Menveo) · For: Meningococcal Disease
Sites: Ansan, South Korea; Anyang, South Korea; Bucheon-si, South Korea · 54 sites in all
- Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young AdultsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04502693 · 3,657 participants · Start Aug 14, 2020 · Primary completion Sep 13, 2022
Drug: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) · For: Infections, Meningococcal
Sites: Chandler, Arizona; Glendale, Arizona; Jonesboro, Arkansas · 112 sites in all
- A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and AdultsPivotal-lookingCompleted
Novartis VaccinesNovartis (NVS)
NCT00450437 · 3,539 participants · Start Mar 2007 · Primary completion Aug 2007
Drug: MenACWY CRM; Meningococcal ACWY Conjugate vaccine · For: Meningococcal Infections; Meningococcal Meningitis
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Fremont, California · 40 sites in all
- Novartis Vaccine and Diagnostics Carriage TrialPivotal-lookingCompleted
Novartis VaccinesNovartis (NVS)
NCT01214850 · 2,968 participants · Start Sep 2010 · Primary completion Jan 2012
Drug: Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ); MenACWY-CRM conjugate vaccine and 1 more · For: N. Meningitidis Carriage
Sites: Surrey, United Kingdom; Bristol, England, United Kingdom; Liverpool, England, United Kingdom · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in USA and Puerto Rico: Results from a Phase III, randomized, active-controlled study.
Moskow A, Gupta S, Dhingra MS, et al. · Hum Vaccin Immunother 2026
- Healthcare professionals' perspectives and preferences regarding adolescent meningococcal disease vaccination in the United States.
Herrera-Restrepo O, Batchelder L, Pinto T, et al. · Expert Rev Vaccines 2026
- Meningococcal meningitis in India: An expert consensus on use of MCVs.
Dutta AK, Dass Hazarika R, Ravikumar KL, et al. · Hum Vaccin Immunother 2026
- Meningococcal vaccination counts and public attention: A time-series study from Türkiye.
Boğa A, Sayman EN, Yldz Silahl N, et al. · Hum Vaccin Immunother 2026
- Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
Hoberman A, Atwi J, Silas P, et al. · Hum Vaccin Immunother 2026
- Sustained salivary IgG but short-lived IgA responses following primary and booster MenACWY-TT vaccination in older adults.
Visser M, van Rooijen DM, Wolf J, et al. · Hum Vaccin Immunother 2026
Also in development for Shigellosis
- Shigella4V2Phase 22 trials
LimmaTech Biologics AG · Shigellosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.